P2RY12 and Patent foramen ovale: Recent evidence suggested that the P2Y12 inhibitor, targeting platelet adenosine diphosphate P2Y12 receptors and specifically inhibiting adenosine diphosphate-stimulated platelet function, may be effective in treating migraine with or without PFO and preventing new-onset migraine following transcatheter ASDC [8–15].